v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Operating Expenses:        
Research and development $ 2,649,673 $ 677,332 $ 3,936,009 $ 1,635,564
Legal and professional 1,286,167 520,364 2,474,387 1,477,909
General and administrative 895,559 984,262 1,384,267 1,833,747
Stock based compensation 5,651,913 3,526,076 8,384,311 20,923,850
Advisory fees 3,586,575 4,946,575 11,737,806
Total Operating Expenses 14,069,887 5,708,034 21,125,549 37,608,876
Loss From Operations (14,069,887) (5,708,034) (21,125,549) (37,608,876)
Other Income (Expense):        
Interest income 334 28,725 5,530 80,424
Grant income 482,778 529,901
Amortization of debt issuance costs (167,951) (192,249) (360,116) (360,200)
Interest expense (234,370) (48,750) (1,216,994) (357,672)
Other income (expense) (189,627) 240,138 (834,228) 240,138
Loss on change in fair value of derivative liability related to Series A preferred stock (61,321) (61,321)
Gain on change in fair value of derivative liability through equity line of credit 2,801
Net Loss $ (14,240,044) $ (5,680,170) $ (23,059,976) $ (38,006,186)
Loss per share:        
Basic net loss per share $ (0.58) $ (0.30) $ (0.96) $ (2.04)
Diluted net loss per share $ (0.58) $ (0.30) $ (0.96) $ (2.04)
Weighted average shares used in computing basic net loss per common share 24,663,745 19,026,776 23,984,419 18,589,859
Weighted average shares used in computing diluted net loss per common share 24,663,745 19,026,776 23,984,419 18,589,859